Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Clover Corporation is an Australian life sciences company focused on the refinement and delivery of high-value Omega-3 fatty acids, specifically docosahexaenoic acid. Through its subsidiaries, including the Australian Fish Oil Company and Nu-Mega Ingredients, the company utilizes proprietary microencapsulation technology to incorporate nutritional oils into infant formula and functional foods. Their flagship Driphorm technology protects sensitive oils from oxidation, ensuring stability and neutral taste in powdered applications. Clover operates globally, providing specialized ingredients to the pharmaceutical, nutraceutical, and pediatric nutrition industries. The company is a key supplier to major global infant formula manufacturers, helping them meet regulatory requirements for essential fatty acid content. Headquartered in Victoria, Australia, Clover is listed on the Australian Securities Exchange and maintains a strong focus on research and development for new bioactive delivery systems.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Australian Fish Oil Company.